Overdiagnosis in lung cancer screening: estimates from the German Lung Cancer Screening intervention Trial
Overdiagnosis is a major potential harm of lung cancer screening; knowing its potential magnitude helps to optimize screening eligibility criteria. The German Lung Screening Intervention Trial (“LUSI”) is a randomized trial among 4052 long-term smokers (2622 men), 50.3 to 71.9 years of age from the...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
06 January 2021
|
| In: |
International journal of cancer
Year: 2021, Jahrgang: 148, Heft: 5, Pages: 1097-1105 |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.33295 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ijc.33295 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.33295 
|
| Verfasserangaben: | Sandra González Maldonado, Erna Motsch, Anke Trotter, Hans-Ulrich Kauczor, Claus-Peter Heussel, Silke Hermann, Sylke Ruth Zeissig, Stefan Delorme, Rudolf Kaaks |
| Zusammenfassung: | Overdiagnosis is a major potential harm of lung cancer screening; knowing its potential magnitude helps to optimize screening eligibility criteria. The German Lung Screening Intervention Trial (“LUSI”) is a randomized trial among 4052 long-term smokers (2622 men), 50.3 to 71.9 years of age from the general population around Heidelberg, Germany, comparing five annual rounds of low-dose computed tomography (n = 2029) with a control arm without intervention (n = 2023). After a median follow-up of 9.77 years postrandomization and 5.73 years since last screening, 74 participants were diagnosed with lung cancer in the control arm and 90 in the screening arm: 69 during the active screening period; of which 63 screen-detected and 6 interval cancers. The excess cumulative incidence in the screening arm (N = 16) represented 25.4% (95% confidence interval: −11.3, 64.3] of screen-detected cancer cases (N = 63). Analyzed by histologic subtype, excess incidence in the screening arm appeared largely driven by adenocarcinomas. Statistical modeling yielded an estimated mean preclinical sojourn time (MPST) of 5.38 (4.76, 5.88) years and a screen-test sensitivity of 81.6 (74.4%, 88.8%) for lung cancer overall, all histologic subtypes combined. Based on modeling, we further estimated that about 48% (47.5% [43.2%, 50.7%]) of screen-detected tumors have a lead time ≥4 years, whereas about 33% (32.8% [28.4%, 36.1%]) have a lead time ≥6 years, 23% (22.6% [18.6%, 25.7%]) ≥8 years, 16% (15.6% [12.2%, 18.3%]) ≥10 years and 11% (10.7% [8.0%, 13.0%]) ≥12 years. The high proportions of tumors with relatively long lead times suggest a major risk of overdiagnosis for individuals with comparatively short remaining life expectancies. |
|---|---|
| Beschreibung: | Zuerst publiziert: 15. September 2020 Gesehen am 08.09.2025 |
| Beschreibung: | Online Resource |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.33295 |